Sun Pharma signs global licensing pact with LIB Therapeutics
In short
Sun Pharma signed a global licensing deal with LIB Therapeutics for lerodalcibep, a once-monthly cholesterol drug. The reporting says LIB will get an upfront payment, later milestone payments, and royalties on sales in the licensed areas.
This could affect Sun Pharma’s cholesterol drug plans and LIB’s revenue. The exact deal size and the licensed territories were not stated in the available reporting.
What the reporting says
Sun Pharma signed a global licensing pact with LIB Therapeutics for the cholesterol drug lerodalcibep, according to the filing cited in the reporting. The source says LIB will receive an upfront payment, future milestone payments and royalties on net sales in the licensed territories. The exact financial terms and territories were not stated in the available reporting.
Why it matters
Sun Pharma’s filing says it has licensed lerodalcibep globally from LIB Therapeutics. The reporting says LIB is due an upfront payment, future milestone payments and royalties based on net sales in the licensed territories. Lerodalcibep is described in the publisher summary as a once-monthly PCSK9 inhibitor for lowering LDL cholesterol. The reporting does not state the deal value or the territories covered.